IL-6-mediated tumorigenicity and antioxidant state in squamous cell carcinoma cells are driven by CD109 via stabilization of IL-6 receptor-alpha and activation of STAT3/NRF2 pathway
This work uncovers a previously unidentified mechanism in which CD109 serves as an essential regulator of IL6Rα expression and IL-6 mediated signaling in SCC cells, promoting stemness and antioxidant state, mechanisms known to mediate therapy resistance in SCC. Our findings establish a mechanistic validation for investigating the therapeutic utility of the CD109/ IL6Rα/STAT3/NRF2 pathway in SCC.
Authors
- Amani Hassan (ORCID: https://orcid.org/0000-0002-7542-6976)
- Tenzin Kungyal (ORCID: https://orcid.org/0000-0003-4827-0264)
- Nahid Golabi
- Anie Philip (ORCID: https://orcid.org/0000-0002-2533-1071)
- Shufeng Zhou (ORCID: https://orcid.org/0000-0003-2715-9823)
- Kenneth W. Finnson (ORCID: https://orcid.org/0000-0003-2930-0595)
- Meryem Blati
- Sampath K. Loganathan (ORCID: https://orcid.org/0000-0002-8809-1466)
- Nader Sadeghi (ORCID: https://orcid.org/0000-0002-3218-2668)
- Nick Bertos
Institutions
- McGill University Health Centre (CA)
- McGill University (CA)
Publication Details
- Journal
- Experimental Hematology and Oncology
- Published
- 2025-05-02
- DOI
- https://doi.org/10.1186/s40164-025-00630-x
- Citations
- 2
- Primary Topic
- Immune cells in cancer
- Type
- article
- Field-Weighted Citation Impact
- 1.59
Funders
- McGill University
- McGill University Health Centre
- Fonds de recherche du Québec
- Canadian Institutes of Health Research